Death Toll From Recalled Chinese Heparin Continues to Rise; Tainted Heparin Still in Circulation

Tuesday, April 29, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

PHILADELPHIA, April 28 The family of a Missouri man who died after suffering adverse reactions to contaminated Chinese Heparin is suing Tyco Healthcare, claiming that the company waited too long to announce a recall of the drug.

And the death toll due to tainted Heparin continues to rise, because this case has not been accounted for by the U.S. Food and Drug Administration, which has been investigating 81 other deaths linked to the tainted blood thinner, says an attorney representing the family of Freddie James Williams Sr.

"Public and medical professionals need to be extremely cautious," says Jeffrey Killino, who is filing what appears to be the first wrongful death lawsuit against Tyco. "This case demonstrates that recalled Heparin is still in circulation, and there may be many more deaths throughout the country linked to it. The family was never notified of the recall, and one month after Freddie's death, his family still has numerous recalled syringes in their possession. No one has contacted them to ensure those syringes were discarded."

Williams, 67, of Neeleyville, Missouri died March 28 -- the same day Tyco Healthcare announced its recall. He suffered a series of severe allergic reactions to pre-filled syringes of contaminated Heparin distributed by the company. Williams, who was using Heparin lock flush syringes at home and in the hospital, experienced the most common adverse reactions: nausea, vomiting, excessive sweating and extremely low blood pressure.

Between January 17 and March 21, three other healthcare companies announced four recalls of adulterated Chinese Heparin originating from a Scientific Protein Laboratories plant in Changzhou, China. Tyco Healthcare was the last company to announce a fifth recall of Chinese Heparin originating from the same SPL plant.

The FDA is currently investigating other deaths of patients who suffered allergic reactions to Heparin between January 2007 and March 2008. On April 21, the FDA issued a warning letter to SPL, after finding numerous violations at the plant, including the failure to control its crude supplies, to test for impurities, to investigate the cause of failed lots and for manufacturing with unclean tanks containing unidentified materials.

The problems began to surface in late November, when the Missouri Department of Health and Senior Services began to tally an outbreak of acute allergic reactions among eight adult and pediatric hemodialysis patients. Missouri state health officials notified the U.S. Centers for Disease Control and Prevention on January 7, 2008. Almost immediately, in response to nationwide alert for similar cases, two dialysis supply companies reported having received at least 50 similar allergic reactions among adult hemodialysis patients at dialysis facilities in several states.

A joint probe with the FDA determined that Heparin manufactured with crude Heparin - the active pharmaceutical ingredient (API) derived from pig intestines - supplied by Chinese plants was the culprit in a spate of deaths that now encompasses patients in the U.S. and at least nine other countries. The investigation discovered that the crude Heparin produced by SPL and Tech Pool, was contaminated with over-sulfated chondroitin sulfate, an over-the-counter dietary supplement used to ease joint pain. Traditional release tests did not detect it, because chondroitin sulfate, derived from animal cartilage, can mimic the API of Heparin.

The tainted Heparin linked to Mr. Williams' death was also supplied by SPL and Tech Pool, a joint venture with manufacturing and processing facilities in China. Baxter Healthcare Corporation, which sold Heparin containing the API provided by the same companies, began its recall on January 17. Baxter shut down its Heparin manufacturing operation in February and launched a secon

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store